Antiandrogens as Monotherapy for Prostate Cancer

@article{Schroeder1998AntiandrogensAM,
  title={Antiandrogens as Monotherapy for Prostate Cancer},
  author={F. Schroeder},
  journal={European Urology},
  year={1998},
  volume={34},
  pages={12 - 17}
}
  • F. Schroeder
  • Published 1998
  • Medicine
  • European Urology
  • Castration or antiandrogen monotherapies remain options for prostate cancer treatment as only marginal benefits have been demonstrated with combined androgen blockade, although it may be that certain subgroups of patient may benefit. Of the nonsteroidal antiandrogens, bicalutamide 150 mg was as effective as castration in M0 patients with significant improvement in sexual interest and physical capacity, but the trial has yet to reach maturity. In M1 patients, bicalutamide 150 mg was not as… CONTINUE READING
    28 Citations
    Quality of Life Issues Relating to Endocrine Treatment Options
    • 50

    References

    SHOWING 1-10 OF 17 REFERENCES
    A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
    • 1,356
    Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.
    • A. Chang, B. Yeap, +8 authors D. Trump
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1996
    • 113